Welcome to LookChem.com Sign In|Join Free

CAS

  • or

13939-69-0

Post Buying Request

13939-69-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

13939-69-0 Usage

Uses

Different sources of media describe the Uses of 13939-69-0 differently. You can refer to the following data:
1. Reactant for synthesis of: A coumarin-based HIV-1 Vpr inhibitor1 Antitumor agents as potent chemosensitizers2 Oxime carbamates as reversible inhibitors of fatty acid amide hydrolase3 Dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes4 Bisarylmaleimide glycogen synthase kinase-3 inhibitors5 Lysosomal acid lipase inhibitors and potential Niemann-Pick type C disease therapeutics6
2. Reactant for synthesis of: A coumarin-based HIV-1 Vpr inhibitor Antitumor agents as potent chemosensitizers Oxime carbamates as reversible inhibitors of fatty acid amide hydrolase Dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes Bisarylmaleimide glycogen synthase kinase-3 inhibitors Lysosomal acid lipase inhibitors and potential Niemann-Pick type C disease therapeutics

Check Digit Verification of cas no

The CAS Registry Mumber 13939-69-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,9,3 and 9 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 13939-69:
(7*1)+(6*3)+(5*9)+(4*3)+(3*9)+(2*6)+(1*9)=130
130 % 10 = 0
So 13939-69-0 is a valid CAS Registry Number.
InChI:InChI=1/C6H10ClNO/c7-6(9)8-4-2-1-3-5-8/h1-5H2

13939-69-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (518522)  1-Piperidinecarbonylchloride  97%

  • 13939-69-0

  • 518522-5G

  • 1,008.54CNY

  • Detail

13939-69-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name piperidine-1-carbonyl chloride

1.2 Other means of identification

Product number -
Other names 1-piperidylcarbonyl chloride

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:13939-69-0 SDS

13939-69-0Relevant articles and documents

ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION

-

Paragraph 1280, (2021/10/11)

The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I), or a prodrug, solvate, enantiomer, st

Cannabidiol carbamate compound, pharmaceutical preparation, preparation method and application

-

Paragraph 0107-0111, (2021/01/30)

The invention relates to a cannabidiol carbamate compound, a medicinal preparation, a preparation method and application, and belongs to the field of compounds for treating and preventing diseases related to aging, Alzheimer's disease and Parkinson's disease. The compound has a structure shown as a formula I or a pharmaceutically acceptable salt of the structure shown as the formula I. The compound has good butyrylcholine esterase resisting activity, shows good application prospect in treatment of Alzheimer's disease, and shows good application potential.

Novel cannabidiol?carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease

Jiang, Xia,Liu, Xin-Hua,Shi, Jingbo,Tang, Wenjian,Wang, Sheng,Wu, Chengyao,Xu, Yingying,Zha, Liang,Zhang, Jing,Zhang, Ziwen,Zuo, Jiawei

, (2021/08/10)

Cannabidiol (CBD) and rivastigmine have been launched as drugs for treating dementia and cholinesterases (ChEs) are ideal drug targets. This study focused on developing novel ChE inhibitors as drug leads against dementia through molecular modeling and fragment reassembly approaches. A potent carbamate fragment binding to active site gorge of BuChE was found via a docking-based structural splicing approach, thus, 17 novel compounds were designed by structural reassembly. Compound C16 was identified as a highly selective potent BuChE inhibitor (IC50 = 5.3 nM, SI > 4000), superior to CBD (IC50 = 0.67 μM). C16 possessed BBB penetrating ability, benign safety, neuroprotection, antioxidant and pseudo-irreversible BuChE inhibition (Kd = 13 nM, k2 = 0.26 min?1), showing good drug-like properties. In vivo studies confirmed that C16 significantly ameliorated the scopolamine-induced cognition impairment, almost entirely recovered the Aβ1?42 (icv)-impaired cognitive function to the normal level, showed better behavioral performance than donepezil and good anti-amyloidogenic effect. Hence, the potential BuChE inhibitor C16 can be developed as a promising disease-modifying treatment of AD.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 13939-69-0